Clinical trials: Advanced Malignant Solid Tumors
Solid Tumors
A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI
The purpose of this study is to assess the effect of concomitant ramucirumab (IMC-1121B) on the pharmacokinetics of irinotecan and its metabolite SN-38 when coadministered with folinic acid and 5-fluorouracil, in participants…
- Trial name
- NCT01634555
- Testing
- Ramucirumab (IMC-1121B), Irinotecan, Folinic acid
- Where
- 5 sites in United States
- Volunteers
- 29 people
- Sponsor
- Eli Lilly and Company
HER2 Expressing or Mutated Advanced Malignant Solid Tumors
A Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors
This is an open-label, phase I study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of GQ1005 and preliminary anti-tumor efficacy in HER2 expressing or mutated advanced malignant solid tumor subjects.
- Trial name
- NCT06154343
- Testing
- GQ1005
- Where
- 20 sites in China
- Volunteers
- 150 people
- Sponsor
- GeneQuantum Healthcare (Suzhou) Co., Ltd.
High-grade Glioma, Solid Tumor, Unspecified, Child
Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors
An open label, non-randomized study in pediatric patients with advanced high-grade gliomas and other solid tumors. The study will be performed in two phases: a dose escalation phase in up to 18 patients following a standard "3+3"…
- Trial name
- NCT04299191
- Testing
- LAM561
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Laminar Pharmaceuticals
Malignant Solid Tumor
A Study Using Olaparib Tablets for Subjects With Advanced Solid Tumours.
This is a phase 1 open label, 4 treatment, 4 sequence and 4 period crossover study in subjects with solid tumours no longer responding to, or eligible for standard therapies, and for whom there are no additional standard…
- Trial name
- IVIVC (NCT03553108)
- Testing
- Olaparib Treatment A, Olaparib Treatment B, Olaparib Treatment C
- Where
- 3 sites in Belgium
- Volunteers
- 18 people
- Sponsor
- AstraZeneca
Ovarian Carcinoma, Fallopian Tube Carcinoma
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
This is a first-in-human, open-label, multi-center, Phase 1, dose-escalation study with expansion cohorts to evaluate NM32-2668 for safety and immunogenicity, to determine the maximal tolerated dose and recommended Phase 2 dose…
- Conditions
- Ovarian Carcinoma, Fallopian Tube Carcinoma, Peritoneal Carcinoma, Endometrial Cancer
- Trial name
- NCT06299163
- Testing
- NM32-2668
- Where
- 11 sites in United States
- Volunteers
- 11 people
- Sponsor
- Numab Therapeutics AG
Advanced Cancer
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread
The purpose of this study is to demonstrate the safety and preliminary activity with triple combinations of relatlimab in combination with nivolumab and BMS-986205, or in combination with nivolumab and ipilimumab in…
- Trial name
- NCT03459222
- Testing
- Relatlimab, Nivolumab, BMS-986205
- Where
- 22 sites in United States, Australia and 5 more
- Volunteers
- 229 people
- Sponsor
- Bristol-Myers Squibb
Advanced Malignant Solid Tumor
A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor
This is A Phase I Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of The anti-CLDN18.2 and CD47 Bispecific Antibody AK132 in Advanced Malignant Solid Tumor
- Trial name
- NCT06166472
- Testing
- AK132
- Where
- 7 sites in China
- Volunteers
- 72 people
- Sponsor
- Akeso
Cancer
A Trial To Assess Safety And Tolerability Of PF-04691502 In Cancer Patients
A phase 1 dose-escalation trial to assess the safety, tolerability, and pharmacodynamics of PF-04691502 in adult cancer patients with solid tumors.
- Trial name
- NCT00927823
- Testing
- PF-04691502
- Where
- 7 sites in United States
- Volunteers
- 37 people
- Sponsor
- Pfizer
Malignant Tumors
A Study of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid Tumors
For Phase I, to assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-364 as a single agent or in combination with tislelizumab in…
- Trial name
- NCT07694765
- Testing
- LM-364 for injection, Tislelizumab
- Where
- 3 sites in Australia
- Volunteers
- 90 people
- Sponsor
- LaNova Medicines Limited
Advanced Solid Malignancies, Malignant Lymphomas
Phase1 Study of Gemcitabine HCl Oral Formulation(D07001-F4) in Patients With Advanced Solid Malignancies and Malignant Lymphomas
Open-label Phase 1 sequential dose-escalation study of 10 increasing doses (3 to 6 patients each)to determine and characterize the DLTs and MTD of gemcitabine HCl oral formulation (D07001-F4).
- Trial name
- NCT01800630
- Testing
- Gemcitabine HCl Oral Formulation
- Where
- 3 sites in Taiwan
- Volunteers
- 37 people
- Sponsor
- InnoPharmax Inc.
Advanced Solid Tumours
A Study of SHR-A1921 for Injection in Subjects With Advanced Solid Tumours
To assess the safety and tolerability of SHR-A1921 in patients with advanced solid tumours, to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and/or recommended phase II dose (RP2D) of SHR-A1921
- Trial name
- NCT05154604
- Testing
- SHR-A1921
- Volunteers
- 156 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Advanced Malignant Solid Tumors
Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors
Phase I multicenter, open-label, dose-escalating clinical and pharmacokinetic trial of PM02734 administered in combination with erlotinib to determine the safety and tolerability and to identify the dose limiting toxicity (DLT)…
- Trial name
- NCT00884845
- Testing
- PM02734 and erlotinib, Erlotinib
- Where
- 3 sites in United States, Spain
- Volunteers
- 35 people
- Sponsor
- PharmaMar
Malignant Neoplasm
A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)
The goal of this study is to learn about the safety of different doses of MK-4700 and if people tolerate them. The study will also measure what happens in a person's body over time when MK-4700 is given alone or with…
- Trial name
- NCT06894771
- Testing
- MK-4700, Pembrolizumab
- Where
- 7 sites in United States, Canada and 1 more
- Volunteers
- 5 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Malignant Tumor
QL1604 Monotherapy for dMMR or MSI-H Advanced Solid Tumors
In this study, patients with previously-treated locally-advanced or metastatic mismatched repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal carcinoma (CRC) and other solid tumors will be treated with…
- Trial name
- NCT04326829
- Testing
- QL1604
- Where
- 2 sites in China
- Volunteers
- 86 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Advanced Solid Tumor
A Study of DB-1202 Monotherapy in Advanced Solid Tumors
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1201 in subjects with advanced solid tumors.
- Trial name
- NCT05785728
- Testing
- DB-1202
- Where
- China
- Volunteers
- 150 people
- Sponsor
- DualityBio Inc.
Neoplasms
A Study of ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan
N-cadherin, a protein involved in blood vessel cell binding and on the surface of many tumor cells, is increased as cancer progresses. ADH-1 blocks N-cadherin.
- Trial name
- NCT00421811
- Testing
- ADH-1, melphalan
- Where
- 7 sites in United States
- Volunteers
- 56 people
- Sponsor
- Adherex Technologies, Inc.
Solid Tumor, Triple-negative Breast Cancer
A Study of LY3435151 in Participants With Solid Tumors
The reason for this study is to see if the study drug LY3435151 is safe in participants with advanced solid tumors.
- Conditions
- Solid Tumor, Triple-negative Breast Cancer, Gastric Adenocarcinoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT04099277
- Testing
- LY3435151, Pembrolizumab
- Where
- 2 sites in United States, Japan
- Volunteers
- 2 people
- Sponsor
- Eli Lilly and Company
Advanced Malignant Solid Tumors
A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors.
The objective of this study is to assess the safety and tolerability of MRG002 in combination with HX008 in patients with HER2-expressed advanced malignant solid tumors; and to , explore the maximum tolerated dose (MTD), and to…
- Trial name
- NCT05338957
- Testing
- MRG002+HX008
- Where
- 5 sites in China
- Volunteers
- 30 people
- Sponsor
- Shanghai Miracogen Inc.
Malignant Ascites
Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody
A Randomized, Controlled, Multi-Center Phase III Clinical Study to Compare the Efficacy and Safety of Recombinant Anti-EpCAM and Anti-CD3 Human-Mouse Chimeric Bispecific Antibody (M701) for Intraperitoneal Injection to…
- Trial name
- NCT06432296
- Testing
- M701, paracentesis
- Where
- 2 sites in China
- Volunteers
- 312 people
- Sponsor
- Wuhan YZY Biopharma Co., Ltd.
Carcinoma, Non-Small-Cell Lung, Mesothelioma
Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma
This study will investigate the effect of oral LBH589 on dextromethorphan, a CYP2D6 substrate, and to assess safety and efficacy of oral LBH589 when used with this co-medication in advanced stage NSCLC or malignant pleural…
- Trial name
- NCT00535951
- Testing
- LBH589
- Where
- 5 sites in United States, Canada
- Volunteers
- 18 people
- Sponsor
- Novartis Pharmaceuticals